ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Temozolomide (Kizfizo)

Treatment of adults with glioblastoma multiforme and children with malignant glioma 

Orphan
CHMP opinion 15 Oct 2026 · ORPHELIA Pharma

Research

Oncology · J Clin Oncol · 2026-07-02

In 478 patients with high-risk low-grade (WHO grade 2) glioma, first-line temozolomide versus radiotherapy made no significant difference to progression-free or overall survival in mature phase III results; post hoc molecular subgroups (351 analysable) showed similar results.

Secondary analysisn = 478
Baumert et al. Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
Oncology · Lancet Oncol · 2026-01-01

Final analysis of a phase 3 trial in 751 participants with 1p/19q non-co-deleted anaplastic glioma: adjuvant temozolomide with radiotherapy improved overall survival (HR 0.65), concurrent did not (HR 0.91). Exploratory IDH-mutant median OS: 12.5 vs 6.0 years.

RCTn = 751
van den Bent et al. Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Oncology · Cancer · 2025-12-01

Extension analysis of a randomised trial in IDH-wild-type, TERT-mutant grade 2/3 glioma (58 patients: 18 RT, 40 CRT incl. 21 added non-randomly): temozolomide chemoradiotherapy vs RT alone was linked to median OS 25.8 vs 17.2 months (HR 0.31), with no grade ≥3 toxicity.

RCTn = 58
Zhang et al. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial
Oncology · Lancet Oncol · 2021-05-14

Second interim analysis in 751 adults with 1p/19q non-co-deleted anaplastic glioma: concurrent temozolomide with radiotherapy was futile (median OS 66·9 vs 60·4 months; HR 0·97), while adjuvant temozolomide improved OS (82·3 vs 46·9 months; HR 0·64).

RCTn = 751
van den Bent et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Oncology · Lancet · 2019-02-14

In 129 of 141 randomised patients with newly diagnosed MGMT-methylated glioblastoma, lomustine-temozolomide plus radiotherapy vs temozolomide chemoradiotherapy: median OS 48·1 vs 31·4 months (HR 0·60, 95% CI 0·35–1·03; p=0·0492). Grade ≥3 events 59% vs 51%.

RCTn = 141
Herrlinger et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.